Last checked at 26 Jul 2011 07:00
Proteome Sciences plc
Appointment of VP Business Development in North America
26th July 2011 Proteome Sciences is pleased to announce the appointment of Glenn Barney as VP Business Development in North America. He brings over 25 years of experience with global pharmaceutical companies and the life science industry with extensive operations and business development expertise including building and managing global sales, service and product support teams and overseeing multiple product launches.
Prior to joining the Proteome Sciences team, Mr. Barney was the VP Business Development for NextGen Sciences Inc. and was responsible for the commercialization of a suite of services for biomarker discovery and development of multiplexed quantitative assays. He held senior positions at Decision Biomarkers and PerkinElmer, Inc. where he significantly increased top-line revenue growth and managed key accounts including Hoffman-La Roche, Pfizer, Novartis, Merck, Abbott, GlaxoSmithKline, Johnson & Johnson and BMS. He was also instrumental in developing product lines and managing product divisions at both PerkinElmer and Thermo Electron. Mr. Barney holds a BA in Biology from Boston University.
Christopher Pearce, Proteome Sciences CEO commented:
"We are delighted to have Glenn Barney join our business at this exciting time in its development, particularly since we have been looking for a long time in the USA for the right person. With his outstanding network in pharma and life sciences together with his background in biomarker services and assay development, Glenn will be an outstanding addition to our team.
"At our AGM we said that we expected that the number of biomarkers and assays would expand from the tau phosphorylation assay and the AD blood biomarker panel launched in 2010, to cover around 50 key biomarkers by the end of 2011. This should double again in 2012 as we complete additional MS assays from our substantial portfolio of proprietary biomarkers in neurodegenerative diseases, neurology and cancer. Following the two most recent collaborations announced with The Moffitt and The Buck Institutes in the USA, these numbers will be further extended in cancers, in particular in breast cancer and cancer pathways.
"Glenn has arrived at the ideal time to drive revenue in North America through our protein biomarker assays and services and we expect PS Biomarker Services™ to address the rapidly growing requirement in this important market."
- Ends -
For further information please contact:
Proteome Sciences plc | |
www.proteomics.com | Tel: +44 (0)1932 865065 |
Christopher Pearce, Chief Executive Officer | christopher.pearce@proteomics.com |
James Malthouse, Finance Director | james.malthouse@proteomics.com |
Dr. Ian Pike, Chief Operating Officer | ian.pike@proteomics.com |
Nominated Adviser | |
Singer Capital Markets Limited | Tel: +44 (0)20 3205 7500 |
Shaun Dobson/Claes Spång | |
Public Relations | |
Financial Dynamics | IKON Associates |
Ben Atwell/Mo Noonan | Adrian Shaw |
Tel: +44 (0)20 7269 7116 | Tel: +44 (0)1483 271291 |
Email: mo.noonan@fd.com | Mobile: +44 (0)7979 900733 |
Email: adrian@ikonassociates.com |
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in biomarkers using applied proprietary proteomics and peptidomics technologies that deliver high sensitivity protein and peptide biomarker discovery, validation and assay development.
In addition to proprietary biomarkers in Alzheimer's, stroke and cancers, Proteome Sciences provides full biomarker outsourcing services including rapid assay development through PS Biomarker Services™ from its Frankfurt ISO 9001:2008 accredited facilities.
Visit: http://www.proteomics.com.